ULTRA-DD

ULTRA-DD is focused on defining and validating novel targets in auto-immune and inflammatory diseases by the use of patient-cell derived assays. This is made possible by our collaborating clinicians and hospitals in Oxford and Stockholm, allowing us excellent access to tissue and cells from e.g. lupus, myositis, ankylosing spondylitis and dupuytren's disease patients. Common co-morbidities for these patients indicate that the disease mechanisms could also be important in other indications, including IBD and RA, which will be explored through collaboration... To address this challenge, we have established a partnership between; i) the clinical academic community which cares for the patients and provides deep disease expertise; ii) the academic research community that provides the molecular and technological insights necessary for mechanistic studies; iii) the industrial pharmaceutical sector with its strength in e.g. the development of high quality chemical and antibody modulators of..